68 results on '"Furman, Richard"'
Search Results
2. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
- Author
-
O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Weiqiang Zhao, Heerema, Nyla A., Johnson, Amy J., Ying Luan, James, Danelle F., Chu, Alvina D., and Byrd, John C.
- Subjects
- *
CANCER chemotherapy , *CANCER patients , *LYMPHOCYTIC leukemia , *CANCER treatment , *PROGRESSION-free survival - Abstract
We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naïve (TN) older patients (≥65 years of age) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We now report on long-term efficacy and safety with median follow-up of 5 years in this patient population with TN (N = 31) and R/R (N = 101) CLL/SLL. With the current 5-year follow-up, ibrutinib continues to yield a high overall response rate of 89%, with complete response rates increasing over time to 29% in TN patients and 10% in R/R patients. The median progression-free survival (PFS) was not reached in TN patients. The 5-year PFS rate was 92% in TN patients and 44% in R/R patients. Median PFS in R/R patients was 51 months; in those with del(11q), del(17p), and unmutated IGHV, it was 51, 26, and 43 months, respectively, demonstrating long-term efficacy of ibrutinib in some high-risk subgroups. Survival outcomes were less robust for R/R patients with del(17p) and those who received more prior therapies. The onset of grade ≥3 cytopenias, such as neutropenia and thrombocytopenia, decreased over time. Treatment--limiting adverse events were more frequent during the first year compared with subsequent periods. These results demonstrate sustained efficacy and acceptable tolerability of ibrutinib over an extended time, providing the longest experience for Bruton tyrosine kinase inhibitor treatment in patients with CLL/SLL. These trials were registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01109069. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia.
- Author
-
Furman, Richard R., Luan, Ying, Bilotti, Elizabeth, and Graef, Thorsten
- Subjects
- *
PROTEIN-tyrosine kinases , *HODGKIN'S disease , *WALDENSTROM'S macroglobulinemia , *PATIENTS - Abstract
A letter to the editor is presented regarding the extended follow-up with ibrutinib, an inhibitor of Bruton's tyrosine kinase, in previously treated patients with the non-Hodgkin lymphoma Waldenström's macroglobulinemia.
- Published
- 2017
- Full Text
- View/download PDF
4. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
- Author
-
Martin, Peter, Furman, Richard R., Rutherford, Sarah, Ruan, Jia, Ely, Scott, Greenberg, June, Coleman, Morton, Goldsmith, Stanley J., and Leonard, John P.
- Subjects
- *
MONOCLONAL antibodies , *B cells , *LYMPHOMA treatment , *IMMUNOTHERAPY , *HODGKIN'S disease , *GENETICS - Abstract
Milatuzumab (hLL1), a humanized anti-CD74 monoclonal antibody, has activity in preclinical non-Hodgkin lymphoma (NHL) models. We conducted a phase 1 trial in previously treated B-cell malignancies. Dose escalation included four planned dose levels (1.5, 4, 6 and 8 mg/kg) with milatuzumab given twice weekly for 6 weeks. After dose level 1, the schedule was changed to daily (Monday–Friday) for 10 days. Twenty-two patients were treated. The most common possibly related toxicities were infusion reaction, anemia, lymphopenia, neutropenia and thrombocytopenia. Three patients experienced dose-limiting toxicity (neutropenia, neutropenia, rash) at dose levels 1, 2 and 4, respectively. Eight patients had stable disease, with no objective responses. The serum half-life of milatuzumab was ∼2 h. In seven patients, In-111 imaging showed no clear evidence of tumor targeting. The short half-life may reflect CD74 rapid internalization and presence on extratumoral tissues; this antigen sink must be overcome to capitalize on the promising preclinical activity of the drug. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
- Author
-
Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Weiqiang Zhao, Heerema, Nyla A., Johnson, Amy J., Yun Shaw, Bilotti, Elizabeth, Cathy Zhou, James, Danelle F., and O'Brien, Susan
- Subjects
- *
CHRONIC lymphocytic leukemia , *LYMPHOMAS , *PROTEIN-tyrosine kinases , *B cell receptors , *INTEGRIN-linked kinase , *PROGRESSION-free survival , *LYMPHOCYTOSIS , *PATIENTS - Abstract
Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL). The durable responses observed with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period. We report on median 3-year follow-up of 132 patients with symptomatic treatment-naïve and relapsed/refractory CLL or small lymphocytic lymphoma. Longer treatment with ibrutinib was associated with improvement in response quality over time and durable remissions. Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections. Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease. Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 year and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better. Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib.
- Author
-
Woyach, Jennifer A., Furman, Richard R., Ta-Ming Liu, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S., Ling Xue, Hsieh-Hsin Li, Daniel, Steggerda, Susanne M., Versele, Matthias, Dave, Sandeep S., Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M., Blum, Kristie A., Lozanski, Arietta, Lozanski, Gerard, James, Danelle F., Barrientos, Jacqueline C., and Lichter, Peter
- Subjects
- *
DRUG resistance in cancer cells , *ANTINEOPLASTIC agents , *PROTEIN-tyrosine kinases , *CHRONIC lymphocytic leukemia treatment , *CANCER patients - Abstract
The article presents a study on the resistance to ibrutinib which is an irreversible inhibitor of Bruton's tyrosine kinase (BTK). Topics include its effectiveness on the treatment of chronic lymphocytic leukemia (CLL), the use of whole-exome sequencing at baseline, and the mutation of cysteine-to-serine in BTK. It also features a table of the characteristics of patients with ibrutinib resistance.
- Published
- 2014
- Full Text
- View/download PDF
7. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.
- Author
-
Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Path, F. R. C., Shuo Ma, Stilgenbauer, Stephan, and Cramer, Paula
- Subjects
- *
PHOSPHATIDYLINOSITOL 3-kinases , *RITUXIMAB , *PLACEBOS , *CHRONIC lymphocytic leukemia , *ADVERSE health care events - Abstract
The article discusses a phase 3 study which assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo in patients with relapsed chronic lymphocytic leukemia (CLL). It cites improvement in progression-free survival, overall response rate, and overall survival in patients receiving idelalisib and rituximab. It also mentions the occurrence of adverse events in some patients.
- Published
- 2014
- Full Text
- View/download PDF
8. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
- Author
-
O'Brien, Susan, Furman, Richard R, Coutre, Steven E, Sharman, Jeff P, Burger, Jan A, Blum, Kristie A, Grant, Barbara, Richards, Donald A, Coleman, Morton, Wierda, William G, Jones, Jeffrey A, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Izumi, Raquel, Hamdy, Ahmed, Chang, Betty Y, Graef, Thorsten, Clow, Fong, and Buggy, Joseph J
- Subjects
- *
PYRIMIDINES , *LEUKEMIA treatment , *TREATMENT of diseases in older people , *CLINICAL trials , *LYMPHOMA treatment , *IMMUNOTHERAPY , *CANCER chemotherapy , *THERAPEUTICS - Abstract
Summary: Background: Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in elderly patients has been restricted by substantial myelosuppression and infection. We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia. Methods: In our open-label phase 1b/2 trial, we enrolled previously untreated patients at clinical sites in the USA. Eligible patients were aged at least 65 years, and had symptomatic chronic lymphocytic leukaemia or small lymphocytic lymphoma requiring therapy. Patients received 28 day cycles of once-daily ibrutinib 420 mg or ibrutinib 840 mg. The 840 mg dose was discontinued after enrolment had begun because comparable activity of the doses has been shown. The primary endpoint was the safety of the dose-fixed regimen in terms of frequency and severity of adverse events for all patients who received treatment. This study is registered with ClinicalTrials.gov, number NCT01105247. Findings: Between May 20, 2010, and Dec 18, 2012, we enrolled 29 patients with chronic lymphocytic leukaemia and two patients with small lymphocytic lymphoma. Median age was 71 years (range 65–84), and 23 (74%) patients were at least 70 years old. Toxicity was mainly of mild-to-moderate severity (grade 1–2). 21 (68%) patients had diarrhoea (grade 1 in 14 [45%] patients, grade 2 in three [10%] patients, and grade 3 in four [13%] patients). 15 (48%) patients developed nausea (grade 1 in 12 [39%] patients and grade 2 in three [10%] patients). Ten (32%) patients developed fatigue (grade 1 in five [16%] patients, grade 2 in four [13%] patients, and grade 3 in one [3%] patient). Three (10%) patients developed grade 3 infections, although no grade 4 or 5 infections occurred. One patient developed grade 3 neutropenia, and one developed grade 4 thrombocytopenia. After a median follow-up of 22·1 months (IQR 18·4–23·2), 22 (71%) of 31 patients achieved an objective response (95% CI 52·0–85·8); four patients (13%) had a complete response, one patient (3%) had a nodular partial response, and 17 (55%) patients had a partial response. Interpretation: The safety and activity of ibrutinib in elderly, previously untreated patients with symptomatic chronic lymphocytic leukaemia, or small lymphocytic lymphoma is encouraging, and merits further investigation in phase 3 trials. Funding: Pharmacyclics, Leukemia and Lymphoma Society, D Warren Brown Foundation, Mr and Mrs Michael Thomas, Harry Mangurian Foundation, P50 CA140158 to Prof J C Byrd MD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia.
- Author
-
Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, lan W., Burger, Jan A., Blum, Kristie A., Grant, Barbara, Sharman, Jeff P., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Sukbuntherng, Juthamas, Chang, Betty Y., Clow, Fong, Hedrick, Eric, Buggy, Joseph J., and James, Danelle F.
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *CHRONIC lymphocytic leukemia treatment , *BIOPSY , *DISEASE progression , *DISEASE relapse ,BONE marrow examination - Abstract
The article presents a multicenter study which explores the effectiveness of ibrutinib against relapsed chronic lymphocytic leukemia (CLL). Bone marrow biopsy was conducted in patients with relapsed CLL to demonstrate the response rate and progression of the disease. Results show a 75% progression-free survival and 83% overall survival rate at 26 months.
- Published
- 2013
- Full Text
- View/download PDF
10. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
- Author
-
Furman, Richard R., Grossbard, Michael L., Johnson, Jeffrey L., Pecora, Andrew L., Cassileth, Peter A., Jung, Sin-Ho, Peterson, Bruce A., Nadler, Lee M., Freedman, Arnold, Bayer, Ruthee-Lu, Bartlett, Nancy L., Hurd, David D., Cheson, Bruce D., and For The Cancer Leukemia Group B And Eastern Cooperative Oncology Group
- Subjects
- *
BONE marrow transplantation , *ADJUVANT treatment of cancer , *STEM cell transplantation , *LYMPHOMAS , *DRUG therapy , *ANTIBODY-toxin conjugates - Abstract
Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively ( p == 0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively ( p == 0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
11. Phase 1 Trial of Bortezomib Plus R-CHOP in Previously Untreated Patients With Aggressive Non-Hodgkin Lymphoma.
- Author
-
Furman, Richard R., Martin, Peter, Ruan, Jia, Cheung, Ying-Kuen K., Vose, Julie M., LaCasce, Ann S., Elstrom, Rebecca, Coleman, Morton, and Leonard, John P.
- Subjects
- *
DRUG efficacy , *RITUXIMAB , *B cell lymphoma , *ANTINEOPLASTIC agents , *LYMPHOMAS , *DOXORUBICIN , *VINCRISTINE , *THERAPEUTICS - Abstract
The article provides information on a study which determined the efficacy and safety of bortezomib in combination with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL). A review of the related literature on DLBCL and MCL is offered. It describes the methods utilized in the study. The occurrence of hematologic toxicities are recorded. It observes that bortezomib is feasible to be added to R-CHOP chemotherapy.
- Published
- 2010
- Full Text
- View/download PDF
12. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.
- Author
-
Furman, Richard R., Forero-Torres, Andres, Shustov, Andrei, and Drachman, Jonathan G.
- Subjects
- *
LYMPHOCYTIC leukemia , *LEUKEMIA , *LYMPHOPROLIFERATIVE disorders , *CONJUNCTIVITIS , *CONJUNCTIVA diseases , *HYPERHIDROSIS - Abstract
Despite advances in therapy, chronic lymphocytic leukemia remains an incurable disease and novel, effective therapies are needed. In this open-label, dose-escalation, phase I study, dacetuzumab (IgG1 humanized monoclonal antibody) was administered to 12 adults, all of whom had received several prior systemic therapies (median, 4; range, 2–11). Intrapatient dose escalation (maximum weekly doses of 3–8 mg/kg) was used to diminish first-dose-related inflammatory symptoms. No dose-limiting toxicities or dose-dependent trends in adverse events (AEs) were observed. The most common AEs (in ≥2 patients) were fatigue, headache, anorexia, conjunctivitis, hyperhidrosis, and night sweats, all of which were mild or moderate. No deaths, serious AEs, or discontinuations due to AEs occurred. Although no patient achieved an objective response, five patients demonstrated stable disease after 1 cycle of therapy, with no discernable correlation between dacetuzumab dose and outcome. This modest single-agent activity may warrant further testing of dacetuzumab in combination with other chronic lymphocytic leukemia therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
13. A narrative poem as a source of qualitative data
- Author
-
Furman, Richard and Cavers, Stan
- Published
- 2005
- Full Text
- View/download PDF
14. Preventive care of older urban American Indians and Alaska natives in primary care.
- Author
-
Buchwald, Dedra, Furman, Richard, Ashton, Suzanne, Manson, Spero, Buchwald, D, Furman, R, Ashton, S, and Manson, S
- Subjects
- *
ELDER care , *OLDER Alaska Natives , *PRIMARY care , *AGE distribution , *AUDIOMETRY , *MAMMOGRAMS , *COMPARATIVE studies , *FECAL occult blood tests , *NATIVE Americans , *INFLUENZA vaccines , *RESEARCH methodology , *MEDICAL cooperation , *MEDICAL protocols , *PNEUMOCOCCAL vaccines , *PREVENTIVE health services , *PRIMARY health care , *RESEARCH , *SMOKING cessation , *CITY dwellers , *EVALUATION research - Abstract
Little is known about prevention among elderly or urban American Indian/Alaska Native (AI/AN) populations. We reviewed the medical records of 550 older urban AI/AN primary care patients to evaluate how frequently preventive measures were received. Adherence to guidelines was examined by a culturally appropriate (> or =50 years) and standard age threshold (> or =65 years), and by performance of preventive measures at any time ("ever") and in the past year. Lifetime performance was inadequate for the many measures, including mammograms (56%), fecal occult blood testing (37%), audiometry (33%), visual acuity testing (50%), smoking cessation counseling (50%), and pneumococcal (22%) and influenza (49%) vaccinations. Performance of the measures was less frequent in the prior year, but did not differ by age threshold. Predictors of adherence included female gender, having insurance, and having more health problems and medications. Nonadherence infrequently resulted from patients' failure to comply with recommendations. We conclude that use of most preventive services among elderly urban AI/ANs is suboptimal and should be improved. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
15. Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
- Author
-
Furman, Richard R., Shuhua Cheng, Pin Lu, Setty, Menu, Perez, Alijandro R., Guo, Ailin, Racchumi, Joelle, Guozhou Xu, Hao Wu, Jiao Ma, Steggerda, Susanne M., Coleman, Morton, Leslie, Christina, and Wang, Y. Lynn
- Subjects
- *
ANTINEOPLASTIC agents , *DRUG dosage , *LYMPHOCYTES , *PROTEIN-tyrosine kinases - Abstract
The article describes the case of a 49-year-old woman who was previously diagnosed for chronic lymphocytic leukemia (CLL). She was a participant of a phase one, dose-escalation study in 2010 wherein she took a daily dose of ibrutinib. Topics include a thymidine-to-adenine mutation at nucleotide 1634, the continuous rise in lymphocyte count despite medication, and the covalent binding of ibrutinib and Bruton's tyrosine kinase (BTK).
- Published
- 2014
- Full Text
- View/download PDF
16. Idelalisib immune-related toxicity is associated with improved treatment response.
- Author
-
Wagner-Johnston, Nina D., Sharman, Jeff, Furman, Richard R., Salles, Gilles, Brown, Jennifer R., Robak, Tadeusz, Gu, Lin, Xing, Guan, Chan, Rebecca J., Rajakumaraswamy, Nishanthan, and Gopal, Ajay K.
- Subjects
- *
FOLLICULAR lymphoma , *NON-Hodgkin's lymphoma , *DRUG side effects , *IMMUNE checkpoint proteins , *CHRONIC lymphocytic leukemia - Abstract
Idelalisib is associated with increased occurrence of immune-related adverse events (irAEs). Clinical observations suggest a correlation between immune checkpoint inhibitor–induced irAEs and survival outcomes in patients with solid tumors; however, this relationship in hematologic malignancies is not well understood. In a post hoc analysis of 3 registrational trials, we explored the relationship between Grade ≥3 diarrhea/colitis and alanine/aspartate transaminase (ALT/AST) elevation incidences and efficacy endpoints in patients with indolent non-Hodgkin lymphoma (iNHL), follicular lymphoma (FL), and chronic lymphocytic leukemia treated with idelalisib. Grade ≥3 diarrhea/colitis was associated with higher overall response rate (ORR) and longer progression-free survival (PFS) for all subgroups. Grade ≥3 ALT/AST elevations were associated with improved duration of response and overall survival for all subgroups and improved ORR and PFS for patients with FL or iNHL. Our analysis in hematologic malignancies showed a trend correlating idelalisib-induced Grade ≥3 irAEs with improved efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
- Author
-
Martin, Peter, Ruan, Jia, Furman, Richard, Rutherford, Sarah, Allan, John, Chen, Zhengming, Huang, Xiangao, DiLiberto, Maurizio, Chen-Kiang, Selina, and Leonard, John P.
- Subjects
- *
MANTLE cell lymphoma , *BORTEZOMIB , *PROTEASOME inhibitors , *CELL cycle - Abstract
In mantle cell lymphoma (MCL), cyclin D1 combines with CDK4/6 to phosphorylate Rb, releasing a break on the G1 to S phase cell cycle. Palbociclib is a specific, potent, oral inhibitor of CDK4/6 capable of inducing a complete, prolonged G1 cell cycle arrest (pG1) in Rb+ MCL cells. The proteasome inhibitor bortezomib is approved by the US Food and Drug Administration for treatment of mantle cell lymphoma. Palbociclib-induced pG1 appears to sensitize MCL cells to killing by low-dose bortezomib, potentially improving its activity and tolerability. We conducted a phase 1 trial of palbociclib plus bortezomib in patients with previously treated MCL (NCT01111188). Patients received palbociclib at 75 mg (dose level 1), 100 mg (dose level 2), or 125 mg (dose levels 3 and 4) on days 1–12 of each 21-day cycle in addition to intravenous bortezomib 1.0 mg/m2 (dose levels 1, 2, 3) or 1.3 mg/m2 (dose level 4) on days 8, 11, 15 and 18. A total of 19 patients with a median age of 64 and an average of 2 prior therapies were enrolled. Two subjects experienced dose limiting toxicity (DLT): thrombocytopenia (dose level 1) and neutropenia (dose level 3). Although no DLTs were seen at dose level 4, all patients required dose delays during cycle 2 due to cytopenias, and the study team decided to stop the trial. Four of 19 patients achieved a clinical response, including one patient with a complete response. Three patients received treatment for more than one year, including one patient receiving single-agent palbociclib for more than 6 years. The combination of palbociclib 125 mg on days 1–12 plus bortezomib 1.0 mg/m2 on days 8, 11, 15, and 18 of a 21-day cycle is feasible and active in previously treated MCL, with the primary toxicity being myelosuppression. The regimen may be worthy of further evaluation in patients with non-blastoid MCL following failure of other newer agents. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
- Author
-
Stephen Jun Fei Chong, Fen Zhu, Dashevsky, Olga, Rin Mizuno, Lai, Jolin X. H., Hackett, Liam, Ryan, Christine E., Collins, Mary C., Iorgulescu, J. Bryan, Guièze, Romain, Penailillo, Johany, Carrasco, Ruben, Yeonjoo C. Hwang, Muñoz, Denise P., Bouhaddou, Mehdi, Yaw Chyn Lim, Catherine J. Wu, Allan, John N., Furman, Richard R., and Boon Cher Goh
- Subjects
- *
BCL-2 proteins , *CHRONIC leukemia , *VENETOCLAX , *B cell lymphoma , *CHRONIC lymphocytic leukemia , *PHOSPHORYLATION , *PROTEIN kinases , *KINASES - Abstract
The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid malignancies such as diffuse large B cell lymphoma (DLBCL) are frequently intrinsically resistant to venetoclax. Although genomic resistance mechanisms such as BCL2 mutations have been described, this probably only explains a subset of resistant cases. Using 2 complementary functional precision medicine techniques -- BH3 profiling and high-throughput kinase activity mapping -- we found that hyperphosphorylation of BCL-2 family proteins, including antiapoptotic myeloid leukemia 1 (MCL-1) and BCL-2 and proapoptotic BCL-2 agonist of cell death (BAD) and BCL-2 associated X, apoptosis regulator (BAX), underlies functional mechanisms of both intrinsic and acquired resistance to venetoclax in CLL and DLBCL. Additionally, we provide evidence that antiapoptotic BCL-2 family protein phosphorylation altered the apoptotic protein interactome, thereby changing the profile of functional dependence on these prosurvival proteins. Targeting BCL-2 family protein phosphorylation with phosphatase-activating drugs rewired these dependencies, thus restoring sensitivity to venetoclax in a panel of venetoclax-resistant lymphoid cell lines, a resistant mouse model, and in paired patient samples before venetoclax treatment and at the time of progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant?
- Author
-
van Besien, Koen and Furman, Richard R.
- Subjects
- *
HOMOGRAFTS , *TRANSPLANTATION of organs, tissues, etc. , *CHRONIC lymphocytic leukemia treatment , *MEDICAL decision making , *CHRONIC diseases - Abstract
In this article the authors discuss the role of allogeneic transplantation in the treatment of chronic lymphocytic leukemia (CLL) and the article "Low Tumor Burden Is Associated With Early B-Cell Reconstitution and Is a Predictor of Favorable Outcome After Non-Myeloablative Stem Cell Transplant for Chronic Lymphocytic Leukemia" by K. Hebenstreit, S. Iacobelli, S. Leiblein et al. within the issue. They are supportive of using the drugs idelalisib and ibrutinib to treat CLL and of only using allogenic transplantation in patients who do not respond to the drugs.
- Published
- 2014
- Full Text
- View/download PDF
20. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
- Author
-
Coutre, Steven, Choi, Michael, Furman, Richard R., Eradat, Herbert, Heffner, Leonard, Jones, Jeffrey A., Chyla, Brenda, Lang Zhou, Agarwal, Suresh, Waskiewicz, Tina, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Wierda, William G., and Davids, Matthew S.
- Subjects
- *
DRUG efficacy , *CHRONIC lymphocytic leukemia treatment , *CHRONIC lymphocytic leukemia , *DISEASE relapse , *HEMATOLOGIC malignancies , *PATIENTS - Abstract
B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activity in patients with CLL, including those who are heavily pretreated or have 17p deletion. This phase 2 study prospectively evaluated venetoclax in patients with R/R CLL after ibrutinib or idelalisib; here we report on patients who received idelalisib as the last BCRi before enrollment. Venetoclax was initiated at 20 mg daily, followed by intrapatient ramp-up to 400 mg daily. Primary objectives included efficacy (objective response rate [ORR]) and safety of venetoclax. The study enrolled 36 patients who previously received idelalisib (ORR, 67% [24/36]); 2 patients achieved complete remission, and 1 had complete remission with incomplete bone marrow recovery. Median progression-free survival (PFS) has not yet been reached; estimated 12-month PFS was 79%. The most common adverse events (AEs; all grades) were neutropenia (56%), diarrhea (42%), upper respiratory tract infection (39%), thrombocytopenia (36%), nausea (31%), fatigue (28%), cough (22%), rash (22%), and anemia (22%). Grade 3 or 4 AEs were primarily hematologic (neutropenia [50%], thrombocytopenia [25%], and anemia [17%]). No patients experienced tumor lysis syndrome. Venetoclax demonstrated promising clinical activity and favorable tolerability in patients with CLL whose disease progressed during or after idelalisib therapy. This trial was registered at www.clinicaltrials.gov as #NCT02141282. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors.
- Author
-
Sharma, Shringi, Pepin, Xavier, Burri, Harini, Zheng, Lianqing, Kuptsova‐Clarkson, Nataliya, de Jong, Anouk, Yu, Ting, MacArthur, Holly L., Majewski, Michal, Byrd, John C., Furman, Richard R., Ware, Joseph A., Mann, James, Ramies, David, Munugalavadla, Veerendra, Sheridan, Louise, and Tomkinson, Helen
- Subjects
- *
BIOAVAILABILITY , *BRUTON tyrosine kinase , *MANTLE cell lymphoma , *CHRONIC lymphocytic leukemia - Abstract
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or previously treated mantle cell lymphoma. As the bioavailability of the acalabrutinib capsule (AC) depends on gastric pH for solubility and is impaired by acid‐suppressing therapies, coadministration with proton‐pump inhibitors (PPIs) is not recommended. Three studies in healthy subjects (N = 30, N = 66, N = 20) evaluated the pharmacokinetics (PKs), pharmacodynamics (PDs), safety, and tolerability of acalabrutinib maleate tablet (AT) formulated with pH‐independent release. Subjects were administered AT or AC (orally, fasted state), AT in a fed state, or AT in the presence of a PPI, and AT or AC via nasogastric (NG) route. Acalabrutinib exposures (geometric mean [% coefficient of variation, CV]) were comparable for AT versus AC (AUCinf 567.8 ng h/mL [36.9] vs 572.2 ng h/mL [38.2], Cmax 537.2 ng/mL [42.6] vs 535.7 ng/mL [58.4], respectively); similar results were observed for acalabrutinib's active metabolite (ACP‐5862) and for AT‐NG versus AC‐NG. The geometric mean Cmax for acalabrutinib was lower when AT was administered in the fed versus the fasted state (Cmax 255.6 ng/mL [%CV, 46.5] vs 504.9 ng/mL [49.9]); AUCs were similar. For AT + PPI, geometric mean Cmax was lower (371.9 ng/mL [%CV, 81.4] vs 504.9 ng/mL [49.9]) and AUCinf was higher (AUCinf 694.1 ng h/mL [39.7] vs 559.5 ng h/mL [34.6]) than AT alone. AT and AC were similar in BTK occupancy. Most adverse events were mild with no new safety concerns. Acalabrutinib formulations were comparable and AT could be coadministered with PPIs, food, or via NG tube without affecting the PKs or PDs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
- Author
-
Kahl, Brad S., Spurgeon, Stephen E., Furman, Richard R., Flinn, Ian W., Coutre, Steven E., Brown, Jennifer R., Benson, Don M., Byrd, John C., Peterman, Sissy, Yoonjin Cho, Yu, Albert, Godfrey, Wayne R., and Wagner-Johnston, Nina D.
- Subjects
- *
PHOSPHATIDYLINOSITOL 3-kinases , *PROTEIN kinase inhibitors , *LYMPHOMA treatment , *PHARMACOKINETICS , *PHARMACODYNAMICS , *DRUG side effects , *ADVERSE health care events , *THERAPEUTICS - Abstract
Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase δ (PI3Kδ), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or refractory mantle cell lymphoma (MCL). Primary outcome was safety and dose-limiting toxicity (DLT). Secondary outcomes were pharmacokinetic parameters, pharmacodynamic effects, overall response rate (ORR), progression-free survival (PFS), and duration of response (DOR). Patients without DLT and no evidence of disease progression after 48 weeks enrolled in the extension study. Patients had median age of 69 years (range, 52-83) and received median of 4 prior therapies (1-14); 17 of 40 patients (43%) were refractory to their most recent treatment. Median duration of idelalisib treatment was 3.5 months (range, 0.7-30.7), with 6 (15%) continuing extension treatment. Common grade ≥3 adverse events (AEs) included (total%/grade ≥3%) diarrhea (40/18), nausea (33/5), pyrexia (28/0), fatigue (25/3), rash (23/3), decreased appetite (20/15), upper respiratory infection(20/0), pneumonia (13/10), and alanine transaminase or aspartate transaminase elevations (60/20). ORR was 16 of 40 patients (40%), with CR in 2 of 40 patients (5%). Median DOR was 2.7 months, median PFS was 3.7 months, and 1-year PFS was 22%. These data provide proof of concept that targeting PI3Kδ is a viable strategy and worthy of additional study in MCL. This trial was registered at www.clinicaltrials.gov as #NCT00710528. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Review: Improving Outcomes for Patients with Burkitt Lymphoma and HIV.
- Author
-
Blinder, Victoria S., Chadburn, Amy, Furman, Richard R., Mathew, Susan, and Leonard, John P.
- Subjects
- *
HIV-positive persons , *HIV , *LYMPHOMAS , *ANTIRETROVIRAL agents , *ANTIVIRAL agents , *B cells , *IMMUNOTHERAPY , *MEDICAL experimentation on humans , *DRUG therapy - Abstract
Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy that occurs with increased frequency among patients infected with HIV. Until recently, the immunocompromised state of patients with HIV and BL was generally deemed to preclude the use of the intensive chemotherapeutic regimens used to treat HIV-negative patients due to toxicity issues. However, the advent of highly active antiretroviral therapy (HAART) and the mounting evidence that less intensive lymphoma regimens are ineffective in BL have led investigators to treat HIV-positive patients with the same chemotherapy now established as the standard of care for immunocompetent patients. Data suggest that these current approaches, along with supportive care, may result in improved patient outcomes. In contrast, the role of adjunctive immunotherapy with rituximab in HIV-BL remains undefined. Further studies, including randomized clinical trials, are needed to better delineate the optimal treatment for patients with this devastating disease. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
24. A Global Battle's Missing Weapon.
- Author
-
Holbrooke, Richard and Furman, Richard
- Subjects
- *
AIDS , *INFECTIOUS disease transmission , *DIAGNOSIS , *SOCIAL stigma - Abstract
Focuses on the impact of the absence of routine testing on the escalation of global cases of AIDS disease. Effects of patient's unawareness on the spread of the disease; Launch of alternative prevention options; Consideration of the social stigma associated with the disease.
- Published
- 2004
25. Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.
- Author
-
Orfali, Nina, Jhanwar, Yuliya, Koo, Calvin, Pasciolla, Michelle, Baldo, Maria, Cuvilly, Edwidge, Furman, Richard, Gergis, Usama, Greenberg, June, Guarneri, Danielle, Hsu, Jing-Mei, Leonard, John P., Mark, Tomer, Mayer, Sebastian, Maignan, Kathleen, Martin, Peter, Opong, Adomah, Pearse, Roger, Phillips, Adrienne, and Rossi, Adriana
- Subjects
- *
AUTOTRANSPLANTATION , *STEM cell transplantation , *LYMPHOMAS , *HEMATOPOIETIC stem cell transplantation , *SALVAGE therapy - Abstract
We evaluate the safety of bendamustine as a bridge to stem cell transplantation (SCT) in patients with relapsed/refractory lymphoma and residual disease after salvage therapy. Thirty-four subjects without complete responses (CR) received bendamustine 200 mg/m2/day for 2 days followed 14 days later by SCT. Sixteen subjects in partial remission (PR) with maximal FDG-PET SUVs ≤8 prior to bendamustine received autologous SCT, while 13 with suboptimal responses were allografted. Five subjects did not proceed to transplant. No bendamustine toxicities precluded transplantation and no detrimental effect on engraftment or early treatment-related mortality (TRM) was attributable to bendamustine. At 1 year, 75% of auto-recipients and 31% of allo-recipients were alive with CR. Two subjects in the autologous arm developed therapy-related myeloid neoplasia (t-MN). In conclusion, a bendamustine bridge to SCT can be administered without early toxicity to patients with suboptimal responses to salvage chemotherapy. However this approach may increase the risk of t-MN. (NCT02059239). Supplemental data for this article is available online at . [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis.
- Author
-
Genzen, Jonathan R., Kawaguchi, Kathy R., and Furman, Richard R.
- Subjects
- *
CLINICAL trials , *MONOCLONAL antibodies , *ELECTROPHORESIS , *BLOOD proteins , *WALDENSTROM'S macroglobulinemia - Abstract
The article offers the authors' insight on a clinical trial that investigates ofatumumab by serum immunofixation electrophoresis (IFE) and serum protein electrophoresis (SPE) for the Waldenstrom macroglobulinemia treatment. The authors say that they observed patients with faint monoclonal IgG-kappa and identified faint monoclonal proteins on the IFE and SPE gels location. They mention that ofatumumab is a human monoclonal IgG1- kappa antibody that targets CD20.
- Published
- 2011
- Full Text
- View/download PDF
27. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia.
- Author
-
Wierda, William G., Byrd, John C., O'Brien, Susan, Coutre, Steven, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Burger, Jan A., Stevens, Don A., Sharman, Jeff, Ghia, Paolo, Flinn, Ian W., Zhou, Cathy, Ninomoto, Joi, James, Danelle F., and Tam, Constantine S.
- Subjects
- *
CHRONIC lymphocytic leukemia , *TUMORS - Abstract
The article highlights the risk of tumour lysis syndrome (TLS) with single-agent ibrutinib with chronic lymphocytic leukaemia. It mentions the Ibrutinib, as first-in-class, once-daily inhibitor of Bruton's tyrosine kinase for treatment of chronic lymphocytic leukaemia; and mentions the TLS risk assessment based on lymph node (LN) bulk and absolute lymphocyte count (ALC).
- Published
- 2019
- Full Text
- View/download PDF
28. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor.
- Author
-
Wierda, William G., Byrd, John C., Davids, Matthew S., Furman, Richard R., Cheson, Bruce D., Barr, Paul M., Eradat, Herbert, Heffner, Leonard, Zhou, Lang, Verdugo, Maria, Potluri, Jalaja, and Choi, Michael
- Subjects
- *
THROMBOPOIETIN receptors , *T cell receptors , *CHRONIC lymphocytic leukemia - Abstract
The article focuses on a study about administering venetoclax therapy for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor, which have changed the treatment paradigm for chronic lymphocytic leukaemia. Information about the oral BCL2 inhibitor venetoclax is presented.
- Published
- 2019
- Full Text
- View/download PDF
29. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
- Author
-
Soumerai, Jacob D., Ni, Ai, Zelenetz, Andrew D., Xing, Guan, Huang, Julie, Adewoye, Adeboye H., Dubowy, Ronald, Dreiling, Lyndah, Furman, Richard R., Jones, Jeffrey, Sharman, Jeffrey P., and Hallek, Michael
- Subjects
- *
CHRONIC lymphocytic leukemia , *IMMUNOGLOBULIN heavy chains , *DELETION mutation - Abstract
The CLL-IPI is a risk-weighted prognostic model for previously untreated patients with chronic lymphocytic leukemia (CLL), but has not been evaluated in patients with relapsed CLL or on novel therapies. We evaluated the CLL-IPI in 897 patients with relapsed/refractory CLL in 3 randomized trials testing idelalisib (PI3Kδ inhibitor). The CLL-IPI identified patients as low (2.2%), intermediate (12.8%), high (48.7%), and very high (36.2%) risk and was prognostic for survival (log-rank p <.0001; C-statistic 0.706). Of CLL-IPI factors, age >65, β2-microglobulin >3.5mg/L, unmutated immunoglobulin heavy chain variable region gene, and deletion 17p/TP53 mutation were independently prognostic, but Rai I-IV or Binet B/C was not. The CLL-IPI is prognostic for survival in relapsed CLL and with idelalisib therapy. However, low/intermediate risk is uncommon, and regression parameters of individual factors in this risk-weighted model appear different in relapsed CLL. Reassessment of the weighting of the individual variables might optimize the model in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
- Author
-
Ruan, Jia, Martin, Peter, Cerchietti, Leandro, Rodriguez, Amelyn, Hyman, David, Calvo-Vidal, Maria Nieves, Furman, Richard R., Coleman, Morton, Leonard, John P., Christos, Paul, Tam, Wayne, Shah, Bijal, Svoboda, Jakub, Schuster, Stephen J., and Smith, Sonali M.
- Subjects
- *
MANTLE cell lymphoma , *RITUXIMAB , *LYMPHOMA treatment , *FOLLOW-up studies (Medicine) , *CANCER prognosis , *SURVIVAL analysis (Biometry) - Abstract
We report 5-year follow-up of a multicenter phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of mantle cell lymphoma (MCL). The regimen includes induction and maintenance with the LR doublet. Treatment was continuous until progression, with optional discontinuation after 3 years. The median age of the 38 participants was 65 years, with MCL international prognostic index scores balanced among low, intermediate, and high risk (34%, 34%, and 32%, respectively). Twenty-seven (75%) of the 36 evaluable patients completed ‡3 years of study treatment. At a median follow-up of 64 months (range, 21-78), the 3-year progression-free survival (PFS) and overall survival (OS) were 80% and 90%, respectively, with 5-year estimated PFS and OS of 64% and 77%, respectively. During maintenance, hematologic adverse events (AEs) included asymptomatic grade 3 or 4 cytopenias (42% neutropenia, 5% thrombocytopenia, 3% anemia) and mostly grade 1 or 2 infections managed in the outpatient setting (45% upper respiratory infection, 21% urinary tract infection, 13% sinusitis, 11% cellulitis, 8% pneumonia). Nonhematologic AEs, such as constitutional and inflammatory symptoms, occurred at reduced frequency and intensity compared with induction. A peripheral blood minimal residual disease (MRD) assay (clonoSEQ) showed MRD-negative complete remission in 8 of 10 subjects who had completed ‡3 years of treatment and with available samples for analysis. With longer follow-up, LR continues to demonstrate durable responses and manageable safety as initial induction and maintenance therapy for MCL. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
- Author
-
Paulus, Aneel, Manna, Alak, Akhtar, Sharoon, Paulus, Shumail M., Sharma, Mayank, Coignet, Marie V., Jiang, Liuyan, Roy, Vivek, Witzig, Thomas E., Ansell, Stephen M., Allan, John, Furman, Richard, Aulakh, Sonikpreet, Manochakian, Rami, Ailawadhi, Sikander, Chanan‐Khan, Asher A., and Sher, Taimur
- Subjects
- *
CD38 antigen , *MONOCLONAL antibodies , *CELL-mediated cytotoxicity , *PHAGOCYTOSIS , *APOPTOSIS - Abstract
Summary: CD38 is expressed on Waldenström macroglobulinaemia (WM) cells, but its role as a therapeutic target remains undefined. With recent approval of the anti‐CD38 monoclonal antibody, daratumumab (Dara), we hypothesized that blocking CD38 would be lethal to WM cells. In vitro Dara treatment of WM cells (including ibrutinib‐resistant lines) elicited antibody‐dependent cellular cytotoxicity (ADCC), complement‐dependent cytotoxicity (CDC), antibody‐dependent cell phagocytosis (ADCP) and direct apoptosis. In vivo, Dara treatment was well tolerated and delayed tumour growth in RPCI‐WM1‐xenografted mice. CD38 is reported to augment B‐cell receptor (BCR) signalling; we noted that Dara significantly attenuated phosphorylated SYK, LYN, BTK, PLCγ2, ERK1/2, AKT, mTOR, and S6 levels, and this effect was augmented by cotreatment with ibrutinib. Indeed, WM cells, including ibrutinib‐resistant WM cell lines treated with the ibrutinib + Dara combination, showed significantly more cell death through ADCC, CDC, ADCP and apoptosis relative to single‐agent Dara or ibrutinib. In summary, we are the first to report the in vitro and in vivo anti‐WM activity of Dara. Furthermore, we show a close connection between BCR and CD38 signalling, which can be co‐targeted with ibrutinib + Dara to induce marked WM cell death, irrespective of acquired resistance to ibrutinib. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
- Author
-
Jones, Jeffrey, Mato, Anthony, Coutre, Steven, Byrd, John C., Furman, Richard R., Hillmen, Peter, Osterborg, Anders, Tam, Constantine, Stilgenbauer, Stephan, Wierda, William G., Heerema, Nyla A., Eckert, Karl, Clow, Fong, Zhou, Cathy, Chu, Alvina D., James, Danelle F., and O'Brien, Susan M.
- Subjects
- *
CHRONIC lymphocytic leukemia treatment , *IMMUNOTHERAPY , *CHRONIC diseases , *LYMPHOCYTIC leukemia , *CLINICAL trials , *CLINICAL immunology - Abstract
Summary: Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1–12), 18% and 79% of evaluable patients had del(11q) or unmutated IGHV, respectively. With a median follow‐up of 28 months, overall response rate was 85% and estimated 30‐month progression‐free and overall survival rates were 57% [95% confidence interval (CI) 50–64] and 69% (95% CI 61–75), respectively. Patients with normal lactate dehydrogenase or no bulky disease had the most favourable survival outcomes. Sustained haematological improvements in haemoglobin, platelet count and absolute neutrophil count occurred in 61%, 67% and 70% of patients with baseline cytopenias, respectively. New onset severe cytopenias and infections decreased in frequency over time. Progression‐free and overall survival with ibrutinib surpass those of other therapies for patients with del(17p) CLL/SLL. These results provide further evidence of the robust clinical activity of ibrutinib in difficult‐to‐treat CLL/SLL populations. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
- Author
-
Jones, Jeffrey A, Mato, Anthony R, Wierda, William G, Davids, Matthew S, Choi, Michael, Cheson, Bruce D, Furman, Richard R, Lamanna, Nicole, Barr, Paul M, Zhou, Lang, Chyla, Brenda, Salem, Ahmed Hamed, Verdugo, Maria, Humerickhouse, Rod A, Potluri, Jalaja, Coutre, Steven, Woyach, Jennifer, and Byrd, John C
- Subjects
- *
LYMPHOCYTIC leukemia , *MEDICATION safety , *NEUTROPENIA , *THROMBOCYTOPENIA , *ANEMIA , *DISEASE relapse , *LEUKEMIA treatment , *VENETOCLAX , *PROTEIN metabolism , *ANTINEOPLASTIC agents , *CHRONIC lymphocytic leukemia , *COMPARATIVE studies , *DRUG administration , *HETEROCYCLIC compounds , *RESEARCH methodology , *MEDICAL cooperation , *ORAL drug administration , *PROGNOSIS , *PROTEIN-tyrosine kinases , *PROTEINS , *RESEARCH , *RESEARCH funding , *SULFONAMIDES , *TIME , *EVALUATION research , *TREATMENT effectiveness , *DISEASE progression , *PROTEIN kinase inhibitors , *CHEMICAL inhibitors - Abstract
Background: Therapy targeting Bruton's tyrosine kinase (BTK) with ibrutinib has transformed the treatment of chronic lymphocytic leukaemia. However, patients who are refractory to or relapse after ibrutinib therapy have poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia. In this study, we assessed the activity and safety of venetoclax in patients with chronic lymphocytic leukaemia who are refractory to or relapse during or after ibrutinib therapy.Methods: In this interim analysis of a multicentre, open-label, non-randomised, phase 2 trial, we enrolled patients aged 18 years or older with a documented diagnosis of chronic lymphocytic leukaemia according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and an Eastern Cooperative Oncology Group performance score of 2 or lower. All patients had relapsed or refractory disease after previous treatment with a BCR signalling pathway inhibitor. All patients were screened for Richter's transformation and cases confirmed by biopsy were excluded. Eligible patients received oral venetoclax, starting at 20 mg per day with stepwise dose ramp-up over 5 weeks to 400 mg per day. Patients with rapidly progressing disease received an accelerated dosing schedule (to 400 mg per day by week 3). The primary endpoint was overall response, defined as the proportion of patients with an overall response per investigator's assessment according to IWCLL criteria. All patients who received at least one dose of venetoclax were included in the activity and safety analyses. This study is ongoing; data for this interim analysis were collected per regulatory agencies' request as of June 30, 2017. This trial is registered with ClinicalTrials.gov, number NCT02141282.Findings: Between September, 2014, and November, 2016, 127 previously treated patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled from 15 sites across the USA. 91 patients had received ibrutinib as the last BCR inhibitor therapy before enrolment, 43 of whom were enrolled in the main cohort and 48 in the expansion cohort recruited later after a protocol amendment. At the time of analysis, the median follow-up was 14 months (IQR 8-18) for all 91 patients, 19 months (9-27) for the main cohort, and 12 months (8-15) for the expansion cohort. 59 (65%, 95% CI 53-74) of 91 patients had an overall response, including 30 (70%, 54-83) of 43 patients in the main cohort and 29 (60%, 43-72) of 48 patients in the expansion cohort. The most common treatment-emergent grade 3 or 4 adverse events were neutropenia (46 [51%] of 91 patients), thrombocytopenia (26 [29%]), anaemia (26 [29%]), decreased white blood cell count (17 [19%]), and decreased lymphocyte count (14 [15%]). 17 (19%) of 91 patients died, including seven because of disease progression. No treatment-related deaths occurred.Interpretation: The results of this interim analysis show that venetoclax has durable clinical activity and favourable tolerability in patients with relapsed or refractory chronic lymphocytic leukaemia whose disease progressed during or after discontinutation of ibrutinib therapy. The durability of response to venetoclax will be assessed in the final analysis in 2019.Funding: AbbVie, Genentech. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
34. Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.
- Author
-
Simon, Matthew S., Westblade, Lars F., Dziedziech, Alexis, Visone, Joseph E., Furman, Richard R., Jenkins, Stephen G., Schuetz, Audrey N., and Kirkman, Laura A.
- Subjects
- *
BABESIOSIS diagnosis , *RITUXIMAB , *BABESIOSIS , *BLOOD testing , *CHRONIC lymphocytic leukemia , *DRUG resistance in microorganisms , *GENOMES , *CASE studies , *GENETIC mutation , *RESEARCH funding , *DISEASE relapse , *AZITHROMYCIN , *ATOVAQUONE - Abstract
Babesiosis treatment failures with standard therapy have been reported, but the molecular mechanisms are not well understood. We describe the emergence of atovaquone and azithromycin resistance associated with mutations in the binding regions of the target proteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
35. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
- Author
-
Jones, Jeffrey A., Hillmen, Peter, Coutre, Steven, Tam, Constantine, Furman, Richard R., Barr, Paul M., Schuster, Stephen J., Kipps, Thomas J., Flinn, Ian W., Jaeger, Ulrich, Burger, Jan A., Cheng, Mei, Ninomoto, Joi, James, Danelle F., Byrd, John C., and O'Brien, Susan M.
- Subjects
- *
HEMORRHAGE , *CHRONIC lymphocytic leukemia , *LYMPHOCYTIC leukemia , *PLATELET aggregation inhibitors , *BLOOD coagulation - Abstract
Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia ( CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
36. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
- Author
-
Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Moreno, Carol, Pagel, John M., Burger, Jan A., Suzuki, Samuel, Sukbuntherng, Juthamas, and Cole, George
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *CHRONIC lymphocytic leukemia , *LYMPHOMA treatment , *PATIENT compliance , *HEALTH outcome assessment , *PHARMACOKINETICS , *PATIENTS , *THERAPEUTICS - Abstract
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours. It is unknown if intermittent interruption of ibrutinib therapy contributes to altered clinical outcomes. We therefore evaluated the effect of ibrutinib dose adherence on patient outcomes in the phase 3 RESONATE trial. The overall mean dose intensity (DI) was 95% with median treatment duration of ~9 months. Pharmacokinetic assessment of ibrutinib exposure at 420-mg dose suggested similar exposure regardless of patient weight or age. As assessed by independent review committee, patients with higher DI experienced longer median progression-free survival (PFS) comparedwith thosewith lower DI regardless of del17p and/or TP53 status. Of 79 patients requiring a drug hold, treatment was restarted at the original dose in 73 (92%) patients. Mean duration of a missed-dose event was 18.7 days (range, 8-56). Patients missing ≥8 consecutive days of ibrutinib had a shorter median PFS vs those missing <8 days (10.9 months vs not reached). These results support sustained adherence to once-daily ibrutinib dosing at 420 mg as clinically feasible to achieve optimal outcomes in patients with previously treated CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
- Author
-
Lian Xu, Tsakmaklis, Nicholas, Guang Yang, Chen, Jiaji G., Xia Liu, Demos, Maria, Kofides, Amanda, Patterson, Christopher J., Meid, Kirsten, Gustine, Joshua, Dubeau, Toni, Palomba, M. Lia, Advani, Ranjana, Castillo, Jorge J., Furman, Richard R., Hunter, Zachary R., and Treon, Steven P.
- Subjects
- *
CELL membranes , *LYMPHOCYTES , *PROTEIN-tyrosine kinases , *B cells , *CXCR4 receptors - Abstract
Ibrutinib produces high response rates and durable remissions in Waldenström macroglobulinemia (WM) that are impacted by MYD88 and CXCR4WHIM mutations. Disease progression can developonibrutinib, although the molecular basis remains to be clarified. We sequenced sorted CD191 lymphoplasmacytic cells from 6WMpatients who progressed after achieving major responses on ibrutinib using Sanger, TA cloning and sequencing, and highly sensitive and allele-specific polymerase chain reaction (AS-PCR) assays that we developed for Bruton tyrosine kinase (BTK) mutations. AS-PCR assays were used to screen patients with and without progressive disease on ibrutinib, and ibrutinib-naıve disease. Targeted next-generation sequencing was used to validate AS-PCR findings, assess for other BTK mutations, and other targets in B-cell receptor and MYD88 signaling. Among the 6 progressing patients, 3 had BTKCys481 variants that included BTKCys481Ser(c.1635G>C and c.1634T>A) and BTKCys481Arg(c.1634T>C). Two of these patients had multiple BTK mutations. Screening of 38 additional patients on ibrutinib without clinical progression identifiedBTKCys481 mutations in 2 (5.1%) individuals, both of whom subsequently progressed. BTKCys481 mutations were not detected in baseline samples or in 100 ibrutinib-naive WM patients. Using mutated MYD88 as a tumor marker, BTKCys481 mutations were subclonal, with a highly variable clonal distribution. Targeted deep-sequencing confirmed AS-PCR findings, and identified an additional BTKCys481Tyr(c.1634G>A) mutation in the 2 patients with multiple otherBTKCys481 mutations, as well asCARD11Leu878Phe(c.2632C>T) andPLCg2Tyr495His(c.1483T>C) mutations. Four of the 5 patients with BTKC481 variants were CXCR4 mutated. BTKCys481 mutations are common in WM patients with clinical progression on ibrutinib, and are associated with mutated CXCR4. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
- Author
-
Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Hamadani, Mehdi, Stilgenbauer, Stephan, Ghia, Paolo, Anasetti, Claudio, Dreger, Peter, Montserrat, Emili, Perales, Miguel-Angel, Alyea, Edwin P., Awan, Farrukh T., Ayala, Ernesto, Barrientos, Jacqueline C., Brown, Jennifer R., Castro, Januario E., Furman, Richard R., Gribben, John, Hill, Brian T., Mohty, Mohamad, and Moreno, Carol
- Subjects
- *
CHRONIC lymphocytic leukemia treatment , *HEMATOPOIETIC stem cell transplantation , *ANTHRACYCLINES , *RANDOMIZED controlled trials , *DISEASE relapse , *THERAPEUTICS - Abstract
We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
39. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
- Author
-
O'Brien, Susan, Jones, Jeffrey A, Coutre, Steven E, Mato, Anthony R, Hillmen, Peter, Tam, Constantine, Österborg, Anders, Siddiqi, Tanya, Thirman, Michael J, Furman, Richard R, Ilhan, Osman, Keating, Michael J, Call, Timothy G, Brown, Jennifer R, Stevens-Brogan, Michelle, Li, Yunfeng, Clow, Fong, James, Danelle F, Chu, Alvina D, and Hallek, Michael
- Subjects
- *
CHRONIC lymphocytic leukemia treatment , *ANTINEOPLASTIC agents , *DELETION mutation , *P53 protein , *MEDICAL centers , *CANCER immunotherapy - Abstract
Background: The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion (del17p) chronic lymphocytic leukaemia have poor responses and survival after chemoimmunotherapy. We assessed the activity and safety of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.Methods: We did a multicentre, international, open-label, single-arm study at 40 sites in the USA, Canada, Europe, Australia, and New Zealand. Patients (age ≥18 years) with previously treated del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma received oral ibrutinib 420 mg once daily until progressive disease or unacceptable toxicity. The primary endpoint was overall response in the all-treated population per International Workshop on Chronic Lymphocytic Leukaemia 2008 response criteria modified for treatment-related lymphocytosis. Preplanned exploratory analyses were progression-free survival, overall survival, sustained haematological improvement, and immunological improvement. Patient enrolment is complete, but follow-up is ongoing. Treatment discontinuation owing to adverse events, unacceptable toxicity, or death were collected as a single combined category. This study is registered with ClinicalTrials.gov, number NCT01744691.Findings: Between Jan 29, 2013, and June 19, 2013, 145 patients were enrolled. The all-treated population consisted of 144 patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma who received at least one dose of study drug, with a median age of 64 years (IQR 57-72) and a median of two previous treatments (IQR 1-3). At the prespecified primary analysis after a median follow-up of 11·5 months (IQR 11·1-13·8), 92 (64%, 95% CI 56-71) of 144 patients had an overall response according to independent review committee assessment; 119 patients (83%, 95% CI 76-88) had an overall response according to investigator assessment. In an extended analysis with median follow-up of 27·6 months (IQR 14·6-27·7), the investigator-assessed overall response was reported in 120 patients (83%, 95% CI 76-89). 24-month progression-free survival was 63% (95% CI 54-70) and 24-month overall survival was 75% (67-81). Sustained haematological improvement was noted in 72 (79%) of 91 patients with any baseline cytopenia. No clinically relevant changes were noted from baseline to 6 months or 24 months in IgA (median 0·4 g/L at baseline, 0·6 g/L at 6 months, and 0·7 g/L at 24 months), IgG (5·0 g/L, 5·3 g/L, and 4·9 g/L), or IgM (0·3 g/L at each timepoint) concentrations. Common reasons for treatment discontinuation were progressive disease in 34 (24%) patients and adverse events, unacceptable toxicity, or death in 24 (17%) patients. Major bleeding occurred in 13 (9%) patients (11 [8%] grade 3-4). Grade 3 or worse infections occurred in 43 (30%) patients, including pneumonia in 19 (13%) patients. In the extended analysis, 38 patients died, 18 as a result of adverse events (four pneumonia, three chronic lymphocytic leukaemia, two Richter's syndrome, two sepsis, and one each of acute myocardial infarction, septic shock, encephalopathy, general deterioration in physical health, abnormal hepatic function, myocardial infarction, and renal infarction).Interpretation: A high proportion of patients had an overall response to ibrutinib and the risk:benefit profile was favourable, providing further evidence for use of ibrutinib in the most difficult subset of patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Ibrutinib represents a clinical advance in the treatment of patients with del17p chronic lymphocytic leukaemia and has been incorporated into treatment algorithms as a primary treatment for these patients.Funding: Pharmacyclics LLC, an AbbVie Company. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
40. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
- Author
-
Pera, Benet, Tang, Tiffany, Marullo, Rossella, Shao-Ning Yang, Ahn, Haelee, Patel, Jayeshkumar, Elstrom, Rebecca, Ruan, Jia, Furman, Richard, Leonard, John, Cerchietti, Leandro, and Martin, Peter
- Subjects
- *
LYMPHOMAS , *B cells , *CANCER chemotherapy - Abstract
Background: Refractory and/or relapsed diffuse large B cell lymphoma (RR-DLBCL) patients are incurable with conventional chemotherapy due to the aggressiveness and the chemorefractory state of these tumors. DNA hypermethylation and histone deacetylation are two major epigenetic modifications by which aggressive DLBCL maintain their oncogenic state. We have previously reported that DNA methyltransferase inhibitors (DNMTI) affect RR-DLBCL growth and improve chemosensitivity. Here, we hypothesized that the combination of DNMTI with histone deacetylase inhibitor (HDI) would be an active and feasible therapeutic strategy in RR-DLBCL. Thus, we evaluated the anti-lymphoma activity of the HDI vorinostat (VST) in combination with the DNMTI azacitidine (AZA) or decitabine (DAC) in pre-clinical models of RR-DLBCL, and we determined the feasibility of the combination by conducting a phase Ib trial in RR-DLBCL patients. Results: Concurrent combination of DNMTI and HDI resulted in synergistic anti-lymphoma effect toward RR-DLBCL cells in vitro and in vivo, with no significant toxicity increase. In a phase Ib trial, a total of 18 patients with a median of three prior therapies were treated with four different dose levels of AZA and VST. The most common toxicities were hematological, followed by gastrointestinal and metabolic. The clinical benefit was low as only one subject had a partial response and three subjects had stable disease. Interestingly, two of the seven patients that received additional chemotherapy post-study achieved a complete response and three others had a significant clinical benefit. These observations suggested that the combination might have a delayed chemosensitization effect that we were able to confirm by using in vitro and in vivo models. These studies also demonstrated that the addition of VST does not improve the chemosensitizing effect of DAC alone. Conclusions: Our data supports the strategy of epigenetic priming by employing DNMTI in RR-DLBCL patients in order to overcome resistance and improve their outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.
- Author
-
Bologna, Cinzia, Buonincontri, Roberta, Serra, Sara, Vaisitti, Tiziana, Audrito, Valentina, Brusa, Davide, Pagnani, Andrea, Coscia, Marta, D'Arena, Giovanni, Mereu, Elisabetta, Piva, Roberto, Furman, Richard R., Rossi, Davide, Gaidano, Gianluca, Terhorst, Cox, and Deaglio, Silvia
- Subjects
- *
CHRONIC lymphocytic leukemia , *CELL adhesion molecules , *GENE silencing , *CHEMOTAXIS , *MONOCLONAL antibodies , *REACTIVE oxygen species , *BCL-2 proteins , *AUTOPHAGY , *CELL receptors , *ANTIGENS , *CELL physiology , *CELL motility , *TRANSFERASES , *PHYSIOLOGY - Abstract
Chronic lymphocytic leukemia (CLL) is a variable disease; therefore, markers to identify aggressive forms are essential for patient management. Here, we have shown that expression of the costimulatory molecule and microbial sensor SLAMF1 (also known as CD150) is lost in a subset of patients with an aggressive CLL that associates with a shorter time to first treatment and reduced overall survival. SLAMF1 silencing in CLL-like Mec-1 cells, which constitutively express SLAMF1, modulated pathways related to cell migration, cytoskeletal organization, and intracellular vesicle formation and recirculation. SLAMF1 deficiency associated with increased expression of CXCR4, CD38, and CD44, thereby positively affecting chemotactic responses to CXCL12. SLAMF1 ligation with an agonistic monoclonal antibody increased ROS accumulation and induced phosphorylation of p38, JNK1/2, and BCL2, thereby promoting the autophagic flux. Beclin1 dissociated from BCL2 in response to SLAMF1 ligation, resulting in formation of the autophagy macrocomplex, which contains SLAMF1, beclin1, and the enzyme VPS34. Accordingly, SLAMF1-silenced cells or SLAMF1(lo) primary CLL cells were resistant to autophagy-activating therapeutic agents, such as fludarabine and the BCL2 homology domain 3 mimetic ABT-737. Together, these results indicate that loss of SLAMF1 expression in CLL modulates genetic pathways that regulate chemotaxis and autophagy and that potentially affect drug responses, and suggest that these effects underlie unfavorable clinical outcome experienced by SLAMF1(lo) patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
- Author
-
Ruan, Jia, Martin, Peter, Shah, Bijal, Schuster, Stephen J., Smith, Sonali M., Furman, Richard R., Christos, Paul, Rodriguez, Amelyn, Svoboda, Jakub, Lewis, Jessica, Katz, Orel, Coleman, Morton, and Leonard, John P.
- Subjects
- *
ANTINEOPLASTIC agents , *DRUG therapy , *CLINICAL trials , *EXANTHEMA , *LONGITUDINAL method , *LYMPHOMAS , *MONOCLONAL antibodies , *NEUTROPENIA , *QUALITY of life , *SICKNESS Impact Profile , *SURVIVAL analysis (Biometry) , *THALIDOMIDE , *FERRANS & Powers Quality of Life Index - Abstract
Background: Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy.Methods: We conducted a single-group, multicenter, phase 2 study with induction and maintenance phases. During the induction phase, lenalidomide was administered at a dose of 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles; the dose was escalated to 25 mg daily after the first cycle if no dose-limiting adverse events occurred during the first cycle and was reduced to 15 mg daily during the maintenance phase. Rituximab was administered once weekly for the first 4 weeks and then once every other cycle until disease progression. The primary end point was the overall response rate. Secondary end points included outcomes related to safety, survival, and quality of life.Results: A total of 38 participants were enrolled at four centers from July 2011 through April 2014. The median age was 65 years. On the basis of the Mantle Cell Lymphoma International Prognostic Index scores, the proportions of participants with low-risk, intermediate-risk, and high-risk disease at baseline were similar (34%, 34%, and 32%, respectively). The most common grade 3 or 4 adverse events were neutropenia (in 50% of the patients), rash (in 29%), thrombocytopenia (in 13%), an inflammatory syndrome ("tumor flare") (in 11%), anemia (in 11%), serum sickness (in 8%), and fatigue (in 8%). At the median follow-up of 30 months (through February 2015), the overall response rate among the participants who could be evaluated was 92% (95% confidence interval [CI], 78 to 98), and the complete response rate was 64% (95% CI, 46 to 79); median progression-free survival had not been reached. The 2-year progression-free survival was estimated to be 85% (95% CI, 67 to 94), and the 2-year overall survival 97% (95% CI, 79 to 99). A response to treatment was associated with improvement in quality of life.Conclusions: Combination biologic therapy consisting of lenalidomide plus rituximab was active as initial therapy for mantle-cell lymphoma. (Funded by Celgene and Weill Cornell Medical College; ClinicalTrials.gov number, NCT01472562.). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
43. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.
- Author
-
Rutherford, Sarah C., Stewart, Eric N., Chen, Zhengming, Chadburn, Amy, Wehrli, Natasha E., van Besien, Koen, Martin, Peter, Furman, Richard R., Leonard, John P., and Cerchietti, Leandro
- Subjects
- *
TRANSLATION initiation factors (Biochemistry) , *RIBAVIRIN , *LYMPHOMA treatment - Published
- 2018
- Full Text
- View/download PDF
44. Management of adverse events associated with idelalisib treatment: expert panel opinion.
- Author
-
Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O'Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, and Zelenetz, Andrew D.
- Subjects
- *
DRUG side effects , *PHOSPHATIDYLINOSITOL 3-kinases , *CLINICAL drug trials , *PNEUMONIA , *DIARRHEA , *COLITIS - Abstract
Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation. An expert panel was convened to review the pathology of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy. This article provides an overview of idelalisib TEAEs reported in clinical trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis. For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or intravenous steroid therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma.
- Author
-
Reiss, Jonathan, Link, Brian, Ruan, Jia, Furman, Richard, Coleman, Morton, Leonard, John, and Martin, Peter
- Subjects
- *
LYMPHOMAS , *RADIOIMMUNOTHERAPY , *CANCER chemotherapy , *FLUDARABINE , *CYCLOPHOSPHAMIDE , *VINCRISTINE , *MYELODYSPLASTIC syndromes , *ACUTE myeloid leukemia - Abstract
Existing data suggest that myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) peak in incidence 5–10 years following exposure to ionizing radiation, while most publications report less than 5 years of follow-up after radioimmunotherapy (RIT). We report the rate of secondary MDS/AML among 60 patients treated with two front-line sequential chemotherapy-RIT trials with over 11 years of follow-up. Among 35 patients evaluated after fludarabine-RIT and 25 patients evaluated after CVP (cyclophosphamide, vincristine, prednisone)-RIT treatment, the crude, cumulative and Kaplan–Meier rates of MDS/AML at 11 years of follow-up from the combined trials were 0.12/person, 0.010/person-year and 14% (95% confidence interval [CI] 5–24%), respectively. Additionally, we found that patients treated with RIT consolidation appear to have durable remissions but that relapses after 10 years do occur. Studies of efficacy and secondary MDS/AML that report fewer than 10 years of follow-up likely underestimate risk. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
- Author
-
Licht, Christoph, Greenbaum, Larry A, Muus, Petra, Babu, Sunil, Bedrosian, Camille L, Cohen, David J, Delmas, Yahsou, Douglas, Kenneth, Furman, Richard R, Gaber, Osama A, Goodship, Timothy, Herthelius, Maria, Hourmant, Maryvonne, Legendre, Christophe M, Remuzzi, Giuseppe, Sheerin, Neil, Trivelli, Antonella, and Loirat, Chantal
- Subjects
- *
ECULIZUMAB , *HEMOLYTIC-uremic syndrome , *KIDNEY diseases , *COMPLEMENT (Immunology) , *MEDICATION safety , *DRUG efficacy , *THERAPEUTICS - Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal and other end-organ damage. We originally conducted two phase 2 studies (26 weeks and 1 year) evaluating eculizumab, a terminal complement inhibitor, in patients with progressing TMA (trial 1) and those with long duration of aHUS and chronic kidney disease (trial 2). The current analysis assessed outcomes after 2 years (median eculizumab exposure 100 and 114 weeks, respectively). At all scheduled time points, eculizumab inhibited terminal complement activity. In trial 1 with 17 patients, the platelet count was significantly improved from baseline, and hematologic normalization was achieved in 13 patients at week 26, and in 15 patients at both 1 and 2 years. The estimated glomerular filtration rate (eGFR) was significantly improved compared with baseline and year 1. In trial 2 with 20 patients, TMA event-free status was achieved by 16 patients at week 26, 17 patients at year 1, and 19 patients at year 2. Criteria for hematologic normalization were met by 18 patients at each time point. Improvement of 15 ml/min per 1.73 m2 or more in eGFR was achieved by 1 patient at week 26, 3 patients at 1 year, and 8 patients at 2 years. The mean change in eGFR was not significant compared with baseline, week 26, or year 1. Eculizumab was well tolerated, with no new safety concerns or meningococcal infections. Thus, a 2-year analysis found that the earlier clinical benefits achieved by eculizumab treatment of aHUS were maintained at 2 years of follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
47. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.
- Author
-
Elstrom, Rebecca L., Ruan, Jia, Christos, Paul J., Martin, Peter, Lebovic, Daniel, Osborne, Joseph, Goldsmith, Stanley, Greenberg, June, Furman, Richard R., Avram, Anca, Putman, Ryan, Chapman, Erica, Mazumdar, Madhu, Griffith, Kent, Coleman, Morton, Leonard, John P., and Kaminski, Mark S.
- Subjects
- *
LYMPHOMA treatment , *RADIOIMMUNOTHERAPY , *BORTEZOMIB , *RADIATION-sensitizing agents , *DRUG dosage - Abstract
Radioimmunotherapy (RIT) is effective treatment for indolent non-Hodgkin lymphomas (NHLs), but response durations are usually limited, especially in aggressive NHL. We hypothesized that administration of bortezomib as a radiosensitizer with RIT would be tolerable and improve efficacy in NHL. This phase 1 dose-escalation study evaluated escalating doses of bortezomib combined with 131I-tositumomab in patients with relapsed/refractory NHL. Twenty-five patients were treated. Treatment was well tolerated, with primarily hematologic toxicity. The maximum tolerated dose (MTD) was determined to be 0.9 mg/m2 bortezomib, in combination with a standard dose of 75 cGy 131I-tositumomab. Sixteen patients responded (64%), including 44% complete responses (CRs), with 82% CR in patients with follicular lymphoma (FL). At a median follow-up of 7 months, median progression-free survival was 7 months, and seven of 11 patients with FL remained in remission at a median of 22 months. In conclusion, bortezomib can be safely administered in combination with 131I-tositumomab with promising response rates. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
- Author
-
de Vos, Sven, Forero-Torres, Andres, Ansell, Stephen M., Kahl, Brad, Cheson, Bruce D., Bartlett, Nancy L., Furman, Richard R., Winter, Jane N., Kaplan, Henry, Timmerman, John, Whiting, Nancy C., Drachman, Jonathan G., and Advani, Ranjana
- Subjects
- *
B cell lymphoma , *CANCER invasiveness , *CANCER chemotherapy , *LYMPHOMA treatment , *MONOCLONAL antibodies , *NEUTROPENIA , *TUMOR treatment - Abstract
Background Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy have a poor prognosis. CD40 is expressed on multiple B-cell neoplasms including DLBCL and is a potential target for immunotherapy. Dacetuzumab (SGN-40), a non-blocking, partial agonist, humanized IgG1, anti-CD40 monoclonal antibody, has previously demonstrated anti-lymphoma activity in a phase I study. Methods A phase II study was undertaken to evaluate the rate and duration of objective responses and safety of single-agent dacetuzumab in relapsed DLBCL. Forty-six adult patients with relapsed/refractory DLBCL received up to 12 cycles of intravenous dacetuzumab using intrapatient dose-escalation to a target dose of 8 mg/kg/week in an initial 5-week cycle, followed by 4-week cycles of 8 mg/kg/week. Study endpoints included rate and duration of objective responses, safety, survival, pharmacokinetics, immunogenicity, and exploratory correlative studies. Results Overall response rate was 9% and disease control rate (complete remission + partial remission + stable disease) was 37%. Common non-hematologic adverse events (AEs) included fatigue, headache, chills, fever, and nausea. The most frequent Grade 3-4 nonhematologic AE was deep venous thrombosis (3 patients). Grade 3-4 lymphopenia (41%), neutropenia (13%), or thrombocytopenia (19%) occurred without associated infection or bleeding. Reversible ocular events, including conjunctivitis and ocular hyperemia, occurred in 8 patients (17%). Patient-specific factors, including Fc-gamma-RIIIa polymorphism, did not appear to correlate with antitumor activity. Conclusions Single-agent dacetuzumab has modest activity and manageable toxicity in unselected patients with relapsed DLBCL. Combination regimens and robust methods of patient selection may be necessary for further development. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
- Author
-
Flinn, Ian W., Kahl, Brad S., Leonard, John P., Furman, Richard R., Brown, Jennifer R., Byrd, John C., Wagner-Johnston, Nina D., Coutre, Steve E., Benson, Don M., Peterman, Sissy, Yoonjin Cho, Webb, Heather K., Johnson, David M., Yu, Albert S., Ulrich, Roger G., Godfrey, Wayne R., Miller, Langdon L., and Spurgeon, Stephen E.
- Subjects
- *
PHOSPHATIDYLINOSITOL 3-kinases , *PROTEIN kinase inhibitors , *LYMPHOMA treatment , *DRUG side effects , *ADVERSE health care events , *THERAPEUTICS - Abstract
Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-δ, was evaluated in a phase I study in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL). Patients had a median (range) age of 64 (32-91) years, 34 (53%) had bulky disease (≥1 lymph nodes ≥5 cm), and 37 (58%) had refractory disease. Patients had received a median (range) of 4 (1-10) prior therapies. Eight dose regimens of idelalisib were evaluated; idelalisib was taken once or twice daily continuously at doses ranging from 50 to 350 mg. After 48 weeks, patients still benefitting (n = 19; 30%) enrolled into an extension study. Adverse events (AEs) occurring In 20% or more patients (total%/grade ≥3%) included diarrhea (36/8), fatigue (36/3), nausea (25/3), rash (25/3), pyrexia (20/3), and chills (20/0). Laboratory abnormalities included neutropenia (44/23), anemia (31/5), thrombocytopenia (25/11), and serum transaminase elevations (48/25). Twelve (19%) patients discontinued therapy due to AEs. Idelalisib induced disease regression in 46/54 (85%) of evaluable patients achieving an overall response rate of 30/64 (47%), with 1 patient having a complete response (1.6%). Median duration of response was 18.4 months, median progression-free survival was 7.6 months. Idelalisib is well tolerated and active in heavily pretreated, relapsed/refractory patients with iNHL. These trials were registered at clinicaltrials.gov as NCT00710528 and NCT01090414. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
- Author
-
Brown, Jennifer R., Byrd, John C., Coutre, Steven E., Benson, Don M., Flinn, Ian W., Wagner-Johnston, Nina D., Spurgeon, Stephen E., Kahl, Brad S., Bello, Celeste, Webb, Heather K., Johnson, Dave M., Peterman, Sissy, Li, Daniel, Jahn, Thomas M., Lannutti, Brian J., Ulrich, Roger G., Yu, Albert S., Miller, Langdon L., and Furman, Richard R.
- Subjects
- *
PHOSPHATIDYLINOSITOL 3-kinases , *PROTEIN kinase inhibitors , *CHRONIC lymphocytic leukemia , *ADVERSE health care events , *CANCER treatment , *THERAPEUTICS - Abstract
In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3Kδ, was evaluated in 54 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) with adverse characteristics including bulky lymphadenopathy (80%), extensive prior therapy (median 5 [range 2-14] prior regimens), treatment-refractory disease (70%), unmutated IGHV(91%), and del17p and/or TP53 mutations (24%). Patients were treated at 6 dose levels of oral idelalisib (range 50-350 mg once or twice daily) and remained on continuous therapy while deriving clinical benefit. Idelalisib-mediated inhibition of PI3Kδ led to abrogation of Akt phosphorylation in patient CLL cells and significantly reduced serum levels of CLL-related chemokines. The most commonly observed grade ≥3 adverse events were pneumonia (20%), neutropenic fever (11 %), and diarrhea (6%). Idelalisib treatment resulted in nodal responses in 81% of patients. The overall response rate was 72%, with 39% of patients meeting the criteria for partial response per IWCLL 2008 and 33% meeting the recently updated criteria of PR with treatment-induced lymphocytosis. The median progression-free survival for all patients was 15.8 months. This study demonstrates the clinical utility of inhibiting the PI3Kδ pathway with idelalisib. Our findings support the further development of idelalisib in patients with CLL. These trials were registered at clinicaltrials.gov as #NCT00710528 and #NCT01090414. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.